Each year, respiratory syncytial virus (RSV) is the number one cause for hospitalization of infants. Although nearly all children are infected with RSV by age two and many cases are minor, high-risk (born with certain heart and lung diseases) and premature infants can develop severe RSV which can lead to serious lung infections like pneumonia and bronchiolitis.
Synagis® is the only FDA approved medication for protecting babies’ lungs from RSV. It is a monthly shot that is administered during RSV season, which typically runs from November through March. At-risk infants are given the first dose upon discharge from their newborn intensive care unit.
This season Synagis® will be available in the clinic setting or may be given in the patient’s home through Children’s Home Care of Dayton. If we are unable to provide the service directly due to insurance conditions, we will coordinate the referral with the approved insurance provider.
We follow the recommended guidelines for Synagis® from the American Academy of Pediatrics. These recommendations are reviewed and endorsed by Dayton Children’s divisions of newborn medicine, pulmonary medicine, infectious disease, pharmacy and therapeutics committee, and professional staff executive committee as well as the division of neonatology at Miami Valley Hospital.
Refer your patients to Synagis. If you have questions or would like more information about this service call Children’s Home Care of Dayton at 937-641-HOME (4663).
Learn more about our strategic roadmap to the future.